Methods for reducing LRRK2 expression
Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.
1. A method comprising administering to an animal having non-LRRK2 mediated Parkinson's disease an oligomeric compound comprising a modified oligonucleotide, wherein the modified oligonucleotide:
a) consists of 12 to 30 linked nucleosides;
b) has a nucleobase sequence that is at least 90% complementary to the nucleobase sequence of SEQ ID NO: 2 or SEQ ID NO: 3; and
c) comprises at least one modified nucleoside comprising a modified sugar moiety and/or at least one modified internucleoside linkage.
2. A method comprising identifying an animal having non-LRRK2 mediated Parkinson's disease and administering to the animal having non-LRRK2 mediated Parkinson's disease an oligomeric compound comprising a modified oligonucleotide, wherein the modified oligonucleotide:
a) consists of 12 to 30 linked nucleosides;
b) has a nucleobase sequence that is at least 90% complementary to the nucleobase sequence of SEQ ID NO: 2 or SEQ ID NO: 3; and
c) comprises at least one modified nucleoside comprising a modified sugar moiety and/or at least one modified internucleoside linkage.
3. The method of claim 1 , wherein the administering results in amelioration of at least one symptom of Parkinson's disease.
4. The method of claim 1 , wherein the oligomeric compound is administered prior to detection of at least one symptom of Parkinson's disease.
5. The method of claim 3 , wherein the at least one symptom of Parkinson's disease is loss of motor function, aggregate formation, or neuron death.
6. The method of claim 3 , wherein the amelioration of at least one symptom of Parkinson's disease is the slowing of progression of at least one symptom, the delay of onset of at least one symptom, or the reduction of severity or frequency of at least one symptom.
7. The method of claim 1 , wherein expression of LRRK2 mRNA and/or LRRK2 protein is reduced in the animal.
8. The method of claim 2 , wherein expression of LRRK2 mRNA and/or LRRK2 protein is reduced in the animal.
9. The method of claim 1 , wherein the oligomeric compound is single-stranded.
10. The method of claim 1 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a modified sugar moiety.
11. The method of claim 10 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety.
12. The method of claim 11 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety having a 2′-4′ bridge, wherein the 2-4′ bridge is selected from —O—CH 2 —; —O—CH 2 —CH 2 ; and —O—CH(CH 3 )—.
13. The method of claim 1 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a modified non-bicyclic sugar moiety.
14. The method of claim 13 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic sugar moiety comprising a 2′-MOE or 2′-OMe.
15. The method of claim 1 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate.
16. The method of claim 15 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate selected from a morpholino, a PNA, a F-HNA, a THP, or a modified THP.
17. The method of claim 1 , wherein the modified oligonucleotide has a sugar motif comprising:
a 5′-region consisting of 1-5 linked 5′-nucleosides;
a central region consisting of 6-10 linked central region nucleosides; and
a 3′-region consisting of 1-5 linked 3′-region nucleosides; wherein each of the 5′-region nucleosides and each of the 3′-region nucleosides comprises a modified sugar moiety and each of the central region nucleosides comprises an unmodified DNA sugar moiety.
18. The method of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, wherein at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.
19. The method of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is either an unmodified phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.
20. The method of claim 1 , wherein the modified oligonucleotide comprises at least one 5-methylcytosine.
21. The method of claim 1 , wherein the oligomeric compound comprises a conjugate group.
22. The method of claim 1 , wherein the oligomeric compound is paired with a second oligomeric compound to form a duplex.
23. The method of claim 1 , wherein the administering is to the central nervous system.
24. The method of claim 1 , wherein the administering is intrathecal administration or intracerebroventricular administration.
25. The method of claim 1 , wherein the administering does not cause toxicity in the periphery.
26. The method of claim 2 , wherein the administering results in amelioration of at least one symptom of Parkinson's disease.
27. The method of claim 26 , wherein the at least one symptom of Parkinson's disease is loss of motor function, aggregate formation, or neuron death.
28. The method of claim 2 , wherein the oligomeric compound is administered prior to detection of at least one symptom of Parkinson's disease.
29. The method of claim 26 , wherein the amelioration of at least one symptom of Parkinson's disease is the slowing of progression of at least one symptom, the delay of onset of at least one symptom, or the reduction of severity or frequency of at least one symptom.
30. The method of claim 2 , wherein the oligomeric compound is single-stranded.
31. The method of claim 2 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a modified sugar moiety.
32. The method of claim 31 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety.
33. The method of claim 32 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety having a 2′-4′ bridge, wherein the 2-4′ bridge is selected from —O—CH 2 —; —O—CH 2 —CH 2 —; and —O—CH(CH 3 )—.
34. The method of claim 2 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a modified non-bicyclic sugar moiety.
35. The method of claim 34 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a non-bicyclic sugar moiety comprising a 2′-MOE or 2′-OMe.
36. The method of claim 2 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate.
37. The method of claim 36 , wherein the modified oligonucleotide comprises at least one modified nucleoside comprising a sugar surrogate selected from a morpholino, a PNA, a F-HNA, a THP, or a modified THP.
38. The method of claim 2 , wherein the modified oligonucleotide has a sugar motif comprising:
a 5′-region consisting of 1-5 linked 5′-nucleosides;
a central region consisting of 6-10 linked central region nucleosides; and
a 3′-region consisting of 1-5 linked 3′-region nucleosides; wherein each of the 5′-region nucleosides and each of the 3′-region nucleosides comprises a modified sugar moiety and each of the central region nucleosides comprises an unmodified DNA sugar moiety.
39. The method of claim 2 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, wherein at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.
40. The method of claim 2 , wherein each internucleoside linkage of the modified oligonucleotide is either an unmodified phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.
41. The method of claim 2 , wherein the modified oligonucleotide comprises at least one 5-methylcytosine.
42. The method of claim 2 , wherein the oligomeric compound comprises a conjugate group.
43. The method of claim 2 , wherein the oligomeric compound is paired with a second oligomeric compound to form a duplex.
44. The method of claim 2 , wherein the administering is to the central nervous system.
45. The method of claim 2 , wherein the administering is intrathecal administration or intracerebroventricular administration.
46. The method of claim 2 , wherein the administering does not cause toxicity in the periphery.
47. The method of claim 1 , wherein the modified oligonucleotide has a nucleobase sequence that is 100% complementary to the nucleobase sequence of SEQ ID NO: 2 or SEQ ID NO: 3.
48. The method of claim 2 , wherein the modified oligonucleotide has a nucleobase sequence that is 100% complementary to the nucleobase sequence of SEQ ID NO: 2 or SEQ ID NO: 3.